Ir a las Transacciones
Consumo & Retail | Salud

Innoxa has sold its eye care activity to Biosynex Group

The private shareholders of Laboratoires Innoxa have sold the company’s eye care activity to Biosynex Group.

Founded in 1920 in Paris by Dr. François Debat, a French pharmacist, Laboratoires Innoxa is a premium brand recognized worldwide for its expertise in the field of ophthalmology and optics. In 2020, the company was acquired by Frédéric and Laetitia Poux, who conducted a complete refoundation of the portfolio. The brand launched its first products in September 2021 and a new patented best-seller – the blue eye drops – in June 2022. Innoxa’s eye care activity now includes seven references with patented formulas, which comply with the latest European health and safety standards. The company’s product portfolio is structured around four areas: eye drops, eye sprays, contactology and optical sprays. The brand distributes its products in several countries, mostly in Europe and Asia, with core markets in France and China. Innoxa has a multichannel strategy with a historical presence in pharmacies and a focus on online platforms such as Amazon.fr and e-parapharmacies.

Founded in 2005, Biosynex is a leading public health player in France and Europe. The group offers innovative healthcare solutions to a wide range of users through two divisions: Biosynex Pharma (specialized in self-diagnostics and family health products) and Biosybex Diagnostic (developing and offering in vitro diagnostic medical devices). The group employs over 500 people, has a presence in 95 countries, and generated approximately US$212 in sales in 2022.

Oaklins’ team in France acted as M&A advisor to Laboratoires Innoxa in this transaction.

Partes

Contáctese con el equipo de la transacción

Ludovic Beaulieu

Socio
Paris, Francia
Oaklins France

Charlotte Delphis

Asociado
Paris, Francia
Oaklins France

Transacciones relacionadas

Bayer AG has entered into a takeover agreement with Cara Care
Salud | TMT

Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Conozca más
AYANDA CAPITAL has added a new investor to its shareholding
Consumo & Retail

AYANDA CAPITAL has added a new investor to its shareholding

A new investor, Thierry Jacobs, has joined AYANDA CAPITAL S.L.’s shareholding with a minority stake.

Conozca más
Goldlight has been acquired by Grenardi Group
Consumo & Retail

Goldlight has been acquired by Grenardi Group

AS Grenardi Group, the largest Baltic jewelry retailer, has acquired Goldlight.

Conozca más